Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2006 1
2007 2
2008 3
2009 3
2011 1
2012 4
2013 3
2015 6
2016 9
2017 6
2018 7
2019 4
2020 5
2021 7
2022 8
2023 10
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
Development of allosteric and selective CDK2 inhibitors for contraception with negative cooperativity to cyclin binding.
Faber EB, Sun L, Tang J, Roberts E, Ganeshkumar S, Wang N, Rasmussen D, Majumdar A, Hirsch LE, John K, Yang A, Khalid H, Hawkinson JE, Levinson NM, Chennathukuzhi V, Harki DA, Schönbrunn E, Georg GI. Faber EB, et al. Among authors: harki da. Nat Commun. 2023 Jun 3;14(1):3213. doi: 10.1038/s41467-023-38732-x. Nat Commun. 2023. PMID: 37270540 Free PMC article.
The current toolbox for APOBEC drug discovery.
Grillo MJ, Jones KFM, Carpenter MA, Harris RS, Harki DA. Grillo MJ, et al. Among authors: harki da. Trends Pharmacol Sci. 2022 May;43(5):362-377. doi: 10.1016/j.tips.2022.02.007. Trends Pharmacol Sci. 2022. PMID: 35272863 Free PMC article. Review.
Rapid resistance profiling of SARS-CoV-2 protease inhibitors.
Moghadasi SA, Biswas RG, Harki DA, Harris RS. Moghadasi SA, et al. Among authors: harki da. bioRxiv [Preprint]. 2023 Feb 27:2023.02.25.530000. doi: 10.1101/2023.02.25.530000. bioRxiv. 2023. PMID: 36909573 Free PMC article. Updated. Preprint.
Rapid resistance profiling of SARS-CoV-2 protease inhibitors.
Moghadasi SA, Biswas RG, Harki DA, Harris RS. Moghadasi SA, et al. Among authors: harki da. Res Sq [Preprint]. 2023 Mar 15:rs.3.rs-2627723. doi: 10.21203/rs.3.rs-2627723/v1. Res Sq. 2023. PMID: 36993515 Free PMC article. Preprint.
Interfering with nucleotide excision by the coronavirus 3'-to-5' exoribonuclease.
Chinthapatla R, Sotoudegan M, Srivastava P, Anderson TK, Moustafa IM, Passow KT, Kennelly SA, Moorthy R, Dulin D, Feng JY, Harki DA, Kirchdoerfer RN, Cameron CE, Arnold JJ. Chinthapatla R, et al. Among authors: harki da. Nucleic Acids Res. 2023 Jan 11;51(1):315-336. doi: 10.1093/nar/gkac1177. Nucleic Acids Res. 2023. PMID: 36546762 Free PMC article.
APOBEC Enzymes as Targets for Virus and Cancer Therapy.
Olson ME, Harris RS, Harki DA. Olson ME, et al. Among authors: harki da. Cell Chem Biol. 2018 Jan 18;25(1):36-49. doi: 10.1016/j.chembiol.2017.10.007. Epub 2017 Nov 16. Cell Chem Biol. 2018. PMID: 29153851 Free PMC article. Review.
Determinants of Oligonucleotide Selectivity of APOBEC3B.
Wagner JR, Demir Ö, Carpenter MA, Aihara H, Harki DA, Harris RS, Amaro RE. Wagner JR, et al. Among authors: harki da. J Chem Inf Model. 2019 May 28;59(5):2264-2273. doi: 10.1021/acs.jcim.8b00427. Epub 2018 Sep 10. J Chem Inf Model. 2019. PMID: 30130104 Free PMC article.
Development of an N-Terminal BRD4 Bromodomain-Targeted Degrader.
Divakaran A, Scholtz CR, Zahid H, Lin W, Griffith EC, Lee RE, Chen T, Harki DA, Pomerantz WCK. Divakaran A, et al. Among authors: harki da. ACS Med Chem Lett. 2022 Sep 29;13(10):1621-1627. doi: 10.1021/acsmedchemlett.2c00300. eCollection 2022 Oct 13. ACS Med Chem Lett. 2022. PMID: 36262390 Free PMC article.
69 results